zh-twzhen
zh-twzhen

NEWS

合一生技股份有限公司 / 2023 / The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at 2023 ADA’s 83rd Scientific Sessions.

The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at 2023 ADA’s 83rd Scientific Sessions.

2023-06-21

Published Date:2023-06-21

Original Link:https://www.onenessbio.com/en/news_detail227_3.htm

No 1 Date of announcement 2023/06/21 Time of announcement 16:55:57
Subject The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at 2023 ADA’s 83rd Scientific Sessions.
To which item it meets paragraph 12 Date of events 2023/06/24
Statement
  1. Date of institutional investor conference:2023/06/24
  2. Time of institutional investor conference:8:45 (TPE time)
  3. Location of institutional investor conference:San Diego, US
  4. Outline of institutional investor conference:
    (1)The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the American Diabetes Association’s 83rd Scientific Sessions in 2023.
    (2)The American Diabetes Association (ADA), founded in 1939, is a well-known medical association for prevention and treatment of diabetes mellitus dedicated to management, treatment and prevention of type 1 diabetes, type 2 diabetes, gestational diabetes, and pre-diabetes.
  5. Any other matters that need to be specified:The presentation slides will be uploaded to Market Observation Post System according to the regulation.